Interim Report January – September 2014

July – September

  · Net sales fell by about 40% to SEK 1,639k (2,750k).

  · Comprehensive income was a loss of SEK 5,545k (loss: 2,740k).

  · Comprehensive income per share totaled SEK -0.25 (-0.17).

  · Cash flow from operating activities during the period was SEK -4,537 (
-3,286k).

  · Cash and cash equivalents including short-term investments amounted to SEK
12,003k (7,470k) at the end of the period. Short-term investments amounted to
SEK 5,000k (3,000k).

January – September

  · Net sales fell by about 10% to SEK 6,153k (6,856k).

  · Loss after financial items was SEK 14,187k (loss: 10,600k).

  · Comprehensive income was a loss of SEK 14,187k (loss: 10,539k).

  · Comprehensive income per share totaled SEK -0.66 (-0.75).

  · Cash flow from operating activities during the period was SEK -16,516k (
-10,966k).
Events after the end of the period

In November, Genovis filed a lawsuit against Promega Corporation for patent
infringement. The suit relates to Promega’s product IdeS Protease, which Genovis
believes infringes US Patent No. 7 666 582. Genovis has an exclusive global
license to the patent, which expires in 2022 and covers Genovis’ product
FabRICATOR®. The lawsuit includes an injunction to prevent Promega from
producing, using, selling or offering for sale the infringing product, as well
as damages. The suit was filed in the United State District Court of Delaware.

Comments from CEO Sarah Fredriksson

After several years of developing new innovative concepts, we have been pleased
to see the enthusiasm with which our products have been received in the market.
Our customers have published more than 50 scientific publications and have seen
strong sales growth. As we now encounter competition from a major player in the
market that affects our revenue stream, it is important to act. Genovis has
chosen to pursue a legal process that requires both resources and energy, but is
necessary for Genovis to retain its intellectual property rights intact.
Moreover, product development is the result of considerable time, effort and
creativity. Our insurance covers most of the cost of this process.

The loss of income can be attributed in part to the fact that our distributors
have now completely stopped stocking our products, which has had an impact on
revenue compared with the same quarter last year. The shift from distribution to
direct sales is essentially completed and all distribution agreements in the US
and Europe will be terminated in three months.

The business is fully focused on the objectives for the year. In August we
improved our service by opening web-based direct sales and we expanded
production so that we can soon produce all products as endotoxin-free laboratory
reagents. All development projects at Genovis and GeccoDots are on track and in
November/December we expect to be able to launch from new products in both
companies.

Sarah Fredriksson

CEO, Genovis AB
For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel: 46
(0)46 -101235 sarah.fredriksson@genovis.com
ABOUT GENOVIS

Genovis’ business concept is to develop, produce and market innovative
technologies that facilitate and enable development of new treatment methods and
diagnostics for customers in the medical device and pharmaceutical industries.
The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis
develops and sells unique enzymes in innovative product formats that facilitate
development and quality control of and biological drugs. GeccoDots uses
nanotechnology to produce a new type of contrast agent that is used in medical
imaging.

Genovis shares are listed on NASDAQ OMX First North, and Consensus is Certified
Adviser for the Company, t: 46 (0)31-745 50 00